Q32 Bio Raises $55M Through Sale of 6.7M Shares and Warrants
QTTB•Q32 Bio has agreed to sell 6,725,000 common shares at $8.00 each and 150,000 pre-funded warrants at $7.9999 per warrant, raising approximately $55 million before fees. The private placement, led by BVF Partners with RA Capital, OrbiMed and Atlas Venture, is expected to close on May 28, 2026.
1. Private Placement Financing Overview
Q32 Bio entered a securities purchase agreement to raise approximately $55 million through a private placement of common stock and pre-funded warrants. The financing is structured to bolster the company’s cash position ahead of ongoing Phase 2 trials for its lead candidate in alopecia areata.
2. Share and Warrant Terms
Under the agreement, Q32 Bio will issue 6,725,000 common shares at $8.00 per share and 150,000 pre-funded warrants priced at $7.9999 each, reflecting an exercise price of $0.0001. The pre-funded warrants are immediately exercisable and will expire once fully exercised.
3. Investor Participation and Placement Agents
The private placement is led by BVF Partners L.P. with participation from RA Capital Management, OrbiMed and Atlas Venture. Morgan Stanley served as lead placement agent and Oppenheimer & Co. acted as placement agent.
4. Closing Conditions and Registration
The transaction is expected to close on May 28, 2026, subject to customary closing conditions. Q32 Bio has committed to filing a registration statement to register the resale of the shares and any shares issued upon warrant exercise.
